To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).
The quantification of tumor volumes was based on a previously described method involving computerized analysis of magnetic resonance (MR) images. Analysis of contrast-enhancing tumor volumes on T1-weighted MR images was conducted for 67 patients who had contrast-enhancing tumors. Measurements of T2 hyperintensity were obtained for all 102 patients in the study.
The presence or absence of preresection enhancement, actual volume of this enhancement, and the percentage of preoperative enhancement as it relates to the total T2 tumor volume did not have a statistically significant relationship to TTP or OS. In addition to age, the volume of residual disease measured on T2-weighted MR images was the most significant predictor of TTP (p < 0.001), and residual contrast-enhancing tumor volume was the most significant predictor of OS (p = 0.003) on multivariate analysis. In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.
Data from this retrospective analysis of a histologically uniform group of hemispheric AAs treated in the MR imaging era suggest that residual tumor volumes, as documented on postoperative imaging studies, may be a prognostic factor for TTP and OS for this patient population.
Abbreviations used in this paper:AA = anaplastic astrocytoma; CI = confidence interval; GBM = glioblastoma multiforme; HR = hazard ratio; KPS = Karnofsky Performance Scale; MR = magnetic resonance; OS = overall survival; POR = percent of resection; RTOG = Radiation Therapy Oncology Group; TTP = time to tumor progression; VRD = volume of residual disease.
Address reprint requests to: G. Evren Keles, M.D., Department of Neurological Surgery, University of California, San Francisco, 505 Parnassus Avenue, M-787, San Francisco, California 94143-0112. email:
CurranWJJrScottCBHortonJNelsonJSWeinsteinASNelsonDF: Does extent of surgery influence outcome for astro-cytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol12:219–2271992
DonahueBScottCBNelsonJSRotmanMMurrayKJNelsonDF: Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys38:911–9141997
GinsbergLEFullerGNHashmiMLeedsNESchomerDF: The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol49:436–4401998
KelesGELambornKRChangSMPradosMDBergerMS: Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastoma multiforme who are undergoing chemotherapy. J Neurosurg100:41–462004
KelesGELundinDALambornKRChangEFOjemannGBergerMS: Intraoperative subcortical stimulation mapping for hemispheric perirolandic gliomas located within or adjacent to the descending motor pathways: evaluation of morbidity and assessment of functional outcome in 294 patients. J Neurosurg100:369–3752004
LawsERParneyIFHuangWAndersonFMorrisAMAsherA: Glioma Outcomes Investigators: Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg99:467–4732003
LevMHOzsunarYHensonJWRasheedAABarestGDHarshGRIV: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol25:214–2212004
OhJHenryRGPirzkallALuYLiXCatalaaI: Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging19:546–5542004
PignattiFvan den BentMCurranDDebruyneCSylvesterRTherasseP: European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol20:2076–20842002